In validating experiments, we examined expression levels of GIHCG and SPINT1-AS1 in seven types of cancer cell lines (thyroid cancer, pancreatic cancer, liver cancer, melanoma, gastric cancer, breast cancer, and colorectal cancer) and Lapatinib IC50 of the same cancer cell lines. This evidence concerns the gene GIHCG and melanoma.